Present and Future Dyslipidemia Therapies for Reducing Cardiovascular Risk and Cardiovascular Disease Incidence

In the last few decades, statins had been widely used to successfully lower ASCVD risk. Despite the efficacy of statins in reducing CVD events in primary and secondary prevention patients, there is still substantial residual risk and initial and recurring CVD events remaining in these patient groups. Dyslipidemia Therapies for Reducing Cardiovascular Disease Risk provides an overview of the latest research and developments in dyslipidemia therapies to combat elevated lipid levels leading to atherosclerotic cardiovascular disease (ASCVD). A translational medicine approach is used to discuss the background on key lipid disorders in the population leading to cardiovascular disease; clinical trial development of the new drug therapies to combat the lipid disorders and their mechanisms of action; and the target patient groups of the therapies and how they address unmet medical needs in cardiovascular disease/lipid disorders. Contributions from leaders in the dyslipidemia, metabolic and cardiology fields, they offer insights into the research and development and medical backgrounds of the new drug therapies, as well as unpublished information regarding the challenges in unmet medical needs with respect to dyslipidemia in the population, clinical trial development of the therapies and future goals for the therapies. Fills the knowledge gap in the range and prevalence of dyslipiddemias in the population - both common and rare dyslipdemias - and the appropriate current therapies to manage these lipid disorders Get up-to-date with the rapidly evolving research/translational medicine, clinical trials for new and emerging therapies on the horizon and new FDA approved drugs being implemented globally Thought leaders in the field provides unpublished insights on the dyslipidemia field, its challenges and goals and what's in the horizon for patient therapies and, further, the best approach to use for patient management in this complex area of cardiology INDICE: 1. The case for updated lower lipid targets for greater cardiovascular risk reduction2. The role of established therapies for LDL-cholesterol lowering - statins and ezetimibe3. PCSK9 monoclonal antibodies and LDL-cholesterol lowering4. PCSK9 siRNAs as novel therapy for elevated LDL-cholesterol in patients at cardiovascular disease risk5. Bempadoic Acid as a novel pathway targeting LDL-cholesterol6. The Role of CETP inhibitors in LDL-cholesterol lowering7. Beyond LDL-cholesterol, Lp(a) as a therapeutic target8. Beyond LDL-cholesterol, triglycerides as a therapeutic target effectively reduced by icosapent ethyl9. Beyond LDL-cholesterol, novel targets: apoCIII, MTP, endothelial lipase and AngPTL3 inhibitors

• ISBN: 978-0-323-90056-0
• Editorial: Academic Press
• Encuadernacion: Rústica
• Páginas: 160
• Fecha Publicación: 01/03/2023
• Nº Volúmenes: 1
• Idioma: Inglés